BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
BridgeBio Pharma (NASDAQ: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the upcoming Bank of America Merrill Lynch Global Healthcare Conference 2025. The company's management team will engage in a fireside chat on Wednesday, May 14 at 2:20 PM PT in Las Vegas, NV.
Investors and interested parties can access the live webcast through BridgeBio's investor relations website. A replay will remain available for 30 days following the presentation.
BridgeBio Pharma (NASDAQ: BBIO), un'azienda biofarmaceutica specializzata nelle malattie genetiche, ha annunciato la sua partecipazione alla prossima Bank of America Merrill Lynch Global Healthcare Conference 2025. Il team di gestione della società parteciperà a una conversazione informale il mercoledì 14 maggio alle 14:20 PT a Las Vegas, NV.
Investitori e interessati potranno seguire la diretta streaming attraverso il sito web delle relazioni con gli investitori di BridgeBio. La registrazione resterà disponibile per 30 giorni dopo la presentazione.
BridgeBio Pharma (NASDAQ: BBIO), una compañía biofarmacéutica especializada en enfermedades genéticas, ha anunciado su participación en la próxima Conferencia Global de Salud de Bank of America Merrill Lynch 2025. El equipo directivo de la empresa participará en una charla informal el miércoles 14 de mayo a las 2:20 PM PT en Las Vegas, NV.
Los inversores y personas interesadas podrán acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de BridgeBio. La repetición estará disponible durante 30 días después de la presentación.
BridgeBio Pharma (NASDAQ: BBIO)는 유전 질환을 전문으로 하는 생명공학 회사로, 다가오는 Bank of America Merrill Lynch 글로벌 헬스케어 컨퍼런스 2025에 참여할 것이라고 발표했습니다. 회사 경영진은 5월 14일 수요일 오후 2시 20분(태평양 시간)에 네바다주 라스베이거스에서 열린 파이어사이드 채팅에 참석합니다.
투자자 및 관심 있는 분들은 BridgeBio 투자자 관계 웹사이트를 통해 생중계 웹캐스트에 접속할 수 있습니다. 발표 후 30일간 다시보기 서비스도 제공됩니다.
BridgeBio Pharma (NASDAQ : BBIO), une entreprise biopharmaceutique spécialisée dans les maladies génétiques, a annoncé sa participation à la prochaine Bank of America Merrill Lynch Global Healthcare Conference 2025. L'équipe de direction de la société participera à une discussion informelle le mercredi 14 mai à 14h20 PT à Las Vegas, NV.
Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via le site web des relations investisseurs de BridgeBio. Une rediffusion sera disponible pendant 30 jours après la présentation.
BridgeBio Pharma (NASDAQ: BBIO), ein biopharmazeutisches Unternehmen, das sich auf genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Bank of America Merrill Lynch Global Healthcare Conference 2025 angekündigt. Das Management-Team des Unternehmens wird am Mittwoch, den 14. Mai um 14:20 Uhr PT in Las Vegas, NV, an einem Gespräch am Kamin teilnehmen.
Investoren und Interessierte können den Live-Webcast über die Investor-Relations-Website von BridgeBio verfolgen. Eine Aufzeichnung wird für 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT.
To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
ir@bridgebio.com
FAQ
When is BridgeBio (BBIO) presenting at the Bank of America Healthcare Conference 2025?
How can I watch BridgeBio's (BBIO) presentation at the Bank of America Healthcare Conference?
How long will BridgeBio's (BBIO) conference presentation replay be available?
What type of presentation will BridgeBio (BBIO) give at the Bank of America Healthcare Conference?
